ADRENAVERSE

Serial Number 98247227
732

Registration Progress

Application Filed
Oct 30, 2023
Under Examination
May 14, 2024
Approved for Publication
Feb 28, 2024
Published for Opposition
Mar 19, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 2 Granted
Due: Nov 14, 2025 83 days

Trademark Image

ADRENAVERSE

Basic Information

Serial Number
98247227
Filing Date
October 30, 2023
Published for Opposition
March 19, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
732
Status Date
Aug 19, 2025
Application
Pending
Classes
005 042

Rights Holder

Aquestive Therapeutics, Inc.

03
Address
30 Technology Drive
Warren, NJ 07059

Ownership History

Aquestive Therapeutics, Inc.

Original Applicant
03
Warren, NJ

Aquestive Therapeutics, Inc.

Owner at Publication
03
Warren, NJ

Legal Representation

Attorney
Carrie Webb Olson

USPTO Deadlines

Next Deadline
83 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
November 14, 2025
Extension Available
Until May 14, 2025

Application History

25 events
Date Code Type Description Documents
Aug 21, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 19, 2025 EX3G S SOU EXTENSION 3 GRANTED Loading...
Aug 19, 2025 EXT3 S SOU EXTENSION 3 FILED Loading...
Aug 19, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 9, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 8, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Apr 8, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 8, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 21, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 16, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 16, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 16, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 26, 2024 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jul 26, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 26, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 26, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 14, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 19, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 19, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 28, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 28, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 12, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 1, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 8, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 2, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Technologies in the nature of pharmaceutical preparations containing prodrugs of epinephrine for the treatment or prevention of a wide-range of conditions, namely, anaphylaxis, asthma, and allergic reactions; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery platform technology, namely, drug delivery agents consisting of prodrugs of epinephrine that facilitate, enhance or promote optimized delivery, dosing management and accuracy, enhanced solubility, enhanced permeability, or enhanced absorption of a wide range of pharmaceutical agents
Class 042
Development of pharmaceutical preparations and medicines; Technology research in the field of pharmaceutical preparations and drug delivery agents; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations

Classification

International Classes
005 042